6/30/23, 12:09 AM V-HeFT II Pathway Feedback Search Clinical Topics Home Studies V HeFT II V HeFT II Disease Heart failure Trial question What is the role of enalapril in male patients with HF and LV dilation or a LVEF < 45%? Study design Multi-center Double blinded RCT Population 804 male patients Inclusion criteria: male patients with HF and LV dilation or an LVEF < 45% Key exclusion criteria: myocardial infarction or cardiac surgery within the previous three months, angina pectoris limiting exercise or requiring long-term medical therapy, serious obstructive valvular disease, or obstructive lung disease Interventions N=403 enalapril (20 mg daily) N=401 hydralazine-isosorbide dinitrate arm (300 mg hydralazine plus 160 mg isosorbide dinitrate daily) Primary outcome Death at 2 years 25.0 % 25 18.8 % 18 12.5 % Significant decrease 6.3 % NNT = 14 0.0 % Enalapril Hydralazine-isosorbide dinitrate arm https://web.pathway.md/studies/recm6DNOnJLMGIrEq 1/2 6/30/23, 12:09 AM V-HeFT II Pathway Significant decrease in death at 2 years (18% vs. 25%; RR 0.72, 95% CI 0.13 to 1.31) Secondary outcomes No significant difference in death in presence of coronary artery disease (14.1% vs. 14.3%; RR 0.87, 95% CI 0.64 to 1.19) Conclusion In male patients with HF and LV dilation or an LVEF < 45%, enalapril was superior to hydralazine-isosorbide dinitrate arm with respect to death at 2 years. Reference Cohn JN, Johnson G, Ziesche S et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991 Aug 1;325(5):303-10. Open reference URL https://web.pathway.md/studies/recm6DNOnJLMGIrEq 2/2